MMCM
VRTX icon

Murphy & Mullick Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Murphy & Mullick Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.56M Sell
3,143
-5
-0.2% -$2.22K 0.97% 23
2026
Q1 		$1.41M Sell
3,148
-38
-1% -$17.7K 1.04% 22
2025
Q4 		$1.44M Sell
3,186
-38
-1% -$16.4K 1.04% 23
2025
Q3 		$1.26M Sell
3,224
-30
-0.9% -$12.5K 0.94% 24
2025
Q2 		$1.49M Sell
3,254
-6
-0.2% -$2.77K 1.21% 20
2025
Q1 		$1.58M Hold
3,260
– – 1.53% 13
2024
Q4 		$1.31M Buy
+3,260
New +$1.51M 1.21% 18

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Murphy & Mullick Capital Management's VRTX Position: Q2 2026 in Review

Murphy & Mullick Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.16% in Q2 2026, selling an estimated $2.22K and leaving 3,143 shares worth $1.56M. The position accounts for 0.97% of the portfolio, ranked #23.

Murphy & Mullick Capital Management first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.58M in Q1 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Murphy & Mullick Capital Management held 3,143 shares of Vertex Pharmaceuticals worth $1.56M as of Q2 2026.
  • Murphy & Mullick Capital Management sold 5 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.22K.
  • Vertex Pharmaceuticals made up 0.97% of Murphy & Mullick Capital Management's portfolio in Q2 2026, its #23 holding.
  • Murphy & Mullick Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Murphy & Mullick Capital Management's Vertex Pharmaceuticals position peaked at $1.58M in Q1 2025.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.